Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Exempting User Fees From Sequester Could Take Flight

This article was originally published in The Tan Sheet

Executive Summary

A bipartisan group of House Appropriations Committee members criticize the current policy of FDA user fee revenue being captured by the mandatory budget cuts. FDA Commissioner Margaret Hamburg says losing user fee revenue is “troubling” to the agency and the private sector.

You may also be interested in...



FDA “People Power” Could Take Sequestration Hit – Hamburg

The FDA commissioner says a budget sequester would slow implementation of FDA Safety and Innovation Act provisions and reduce some overseas inspections. More emphasis could be placed on using systems that target the riskiest facilities to reduce the number of onsite inspections, Hamburg says.

Rare Cancer Development Consortium Moving Toward Target Selection

An upcoming public meeting will include a look at platforms before the first targets are chosen.

Stealth’s Elamipretide Gets US FDA Review, But Same Questions Linger

The Barth Syndrome candidate application will be reviewed by the FDA, but Stealth BioTherapeutics' CEO tells the Pink Sheet that the company still does not have clear guidance on how or whether it should gather additional clinical data.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106412

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel